ArticleNature2018
Functional genomic landscape of acute myeloid leukaemia.
Registry-linked trialAbstract readComparative Study
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05025098 (Precision Therapy Versus Standard Therapy in Acute Myeloid Leukaemia and Myelodysplastic Syndrome in Elderly), which is not on this map. Cited by 896 papers.
0numbers the graph read from it
0cells of the map it votes in
896citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Precision Therapy Versus Standard Therapy in Acute Myeloid Leukaemia and Myelodysplastic Syndrome in Elderly
Who cites it
896 citing papers in PubMed.
- Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.NEJM evidence · 2026Trial
- Prognostic impact of age and MDS-associated mutations inBlood neoplasia · 2026Article
- Identification of long non-coding RNAs involved in leukemogenesis and venetoclax response in acute myeloid leukemia through functional CRISPR-dCas9 interference screens.Non-coding RNA research · 2026Article
- Article
- Tumor suppressor-like mutations mark a dosage-constrained dependency in leukemia.bioRxiv : the preprint server for biology · 2026Article
- Review
- AI-enabled multi-omics pharmacogenomic modeling guides resistance-aware multitarget optimization of venetoclax therapy in acute myeloid leukemia.NPJ precision oncology · 2026Article
- LPCAT3 is essential for leukemia progression and represents a therapeutic vulnerability in AML.Blood science (Baltimore, Md.) · 2026Article
- Prognostic Significance of Secondary-Type Mutations in NPM1-Mutated Acute Myeloid Leukemia.Cancer medicine · 2026Article
- The Znf711-Phf8 complex functions as a transcriptional rheostat essential for neutrophil development.Haematologica · 2026Article
- Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy.Haematologica · 2026Article
- Article
- Article
- Co-option of lineage plasticity as a hallmark of multipotent acute leukemias.Blood neoplasia · 2026Review
- Multilayer modeling reveals an endogenous retrovirus signature predictive of induction chemotherapy failure in AML.Blood neoplasia · 2026Article
- m6A and NuRD complexes regulate monocytic differentiation and resistance to BCL2/BCL2L1 inhibitors in acute myeloid leukemia.Haematologica · 2026Article
- Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia.Nature cell biology · 2026Article
- FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.Research square · 2026Article
- Article
- FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.bioRxiv : the preprint server for biology · 2026Article
836 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
88 authors.
Jeffrey W TynerDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Cristina E TognonKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Daniel BottomlyKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Beth WilmotKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Stephen E KurtzKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Samantha L SavageDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Nicola LongKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Anna Reister SchultzDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Elie TraerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Melissa AbelDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Anupriya AgarwalKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Aurora BlucherKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Uma BorateKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Jade BryantDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Russell BurkeKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Amy CarlosKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Richie CarpenterKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Joseph CarrollKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Bill H ChangKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Cody CoblentzKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Amanda d'AlmeidaDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Rachel CookKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Alexey DanilovKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Kim-Hien T DaoKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Michie DegninKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Deirdre DevineKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
James DibbKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
David K EdwardsDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Christopher A EideKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Isabel EnglishKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Jason GloverKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Rachel HensonKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Hibery HoKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Abdusebur JemalKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Kara JohnsonKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Ryan JohnsonKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Brian JunioKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Andy KaempfKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Jessica LeonardKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Chenwei LinKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Selina Qiuying LiuKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Pierrette LoKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Marc M LoriauxKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Samuel LutyKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Tara MaceyKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Jason MacManimanDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Jacqueline MartinezDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Motomi MoriKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Dylan NelsonHigh-Throughput Screening Services Laboratory, Oregon State University, Corvalis, OR, USA.
Ceilidh NicholsKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Jill PetersKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Justin RamsdillDivision of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA.
Angela RofeltyDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Robert SchuffDivision of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA.
Robert SearlesKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Erik SegerdellKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Rebecca L SmithKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Stephen E SpurgeonKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Tyler SweeneyKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Aashis ThapaKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Corinne VisserKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Jake WagnerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Kevin Watanabe-SmithKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Kristen WerthKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Joelle WolfKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Libbey WhiteKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Amy YatesDivision of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA.
Haijiao ZhangDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
Christopher R CogleDepartment of Medicine, Division of Hematology and Oncology, University of Florida, Gainesville, FL, USA.
Robert H CollinsDepartment of Internal Medicine/Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Denise C ConnollyMolecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Michael W DeiningerDivision of Hematology & Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Leylah DrusboskyDepartment of Medicine, Division of Hematology and Oncology, University of Florida, Gainesville, FL, USA.
Christopher S HouriganNational Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Craig T JordanDivision of Hematology, University of Colorado, Denver, CO, USA.
Patricia KropfBone Marrow Transplant Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Tara L LinDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS, USA.
Micaela E MartinezClinical Research Services, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Bruno C MedeirosDepartment of Medicine-Hematology, Stanford University, Stanford, CA, USA.
Rachel R PallapatiClinical Research Services, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Daniel A PollyeaDivision of Hematology, University of Colorado, Denver, CO, USA.
Ronan T SwordsDepartment of Hematology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Justin M WattsDepartment of Hematology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Scott J WeirDepartment of Toxicology, Pharmacology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
David L WiestBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Ryan M WintersFox Chase Cancer Center Biosample Repository Facility, Philadelphia, PA, USA.
Shannon K McWeeneyKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. mcweeney@ohsu.edu.
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. drukerb@ohsu.edu.
Funding
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4MUnderstanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5MRADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3MTRAINING PROGRAM IN HEALTH INFORMATICST15LM007088 · NLM · OREGON HEALTH & SCIENCE UNIVERSITY · PI WILLIAM R HERSH, Vishnu Mohan · 1992 to 2026
$23.4MDetection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0MTumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMLU54CA224019 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jeffrey Wallace Tyner · 2017 to 2026
$13.9MOregon Clinical and Translational Research Institute KL2 SupplementKL2TR002370 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Catherine Lee Hough · 2017 to 2026
$10.1MFunctional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic MalignanciesU01CA217862 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J, TYNER, JEFFREY WALLACE · 2017 to 2021
$5.3MRegulation of hematopoiesis by ribosomal protein paralogsR37AI110985 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI DAVID L. WIEST · 2020 to 2026
$4.2MAn Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.R01CA214428 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KEMP, CHRISTOPHER J · 2018 to 2022
$3.0MRegulation of Hematopoiesis by Ribosomal Protein ParalogsR01AI110985 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI WIEST, DAVID L. · 2015 to 2019
$2.0MOregon Clinical and Translational Research InstituteKL2TR000152 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLISON, DAVID H · 2012 to 2015
$1.7MHoward Hughes Medical InstituteNCATS NIH HHS KL2 TR000152NCATS NIH HHS KL2 TR002370NCATS NIH HHS UL1 TR002366NCATS NIH HHS UL1 TR002369NCI NIH HHS K99 CA237630NCI NIH HHS P30 CA069533NCI NIH HHS R01 CA183974NCI NIH HHS R01 CA214428NCI NIH HHS U01 CA217862NCI NIH HHS U54 CA224019NIAID NIH HHS R37 AI110985NLM NIH HHS T15 LM007088
Abstract
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Here we report initial findings from the Beat AML programme on a cohort of 672 tumour specimens collected from 562 patients. We assessed these specimens using whole-exome sequencing, RNA sequencing and analyses of ex vivo drug sensitivity. Our data reveal mutational events that have not previously been detected in AML. We show that the response to drugs is associated with mutational status, including instances of drug sensitivity that are specific to combinatorial mutational events. Integration with RNA sequencing also revealed gene expression signatures, which predict a role for specific gene networks in the drug response. Collectively, we have generated a dataset-accessible through the Beat AML data viewer (Vizome)-that can be leveraged to address clinical, genomic, transcriptomic and functional analyses of the biology of AML.
Indexed as
GenomicsCore Binding Factor Alpha 2 SubunitDatasets as TopicDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AExomeFemaleGene Expression Regulation, NeoplasticGenome, HumanHumansLeukemia, Myeloid, AcuteMaleMolecular Targeted TherapyNuclear ProteinsNucleophosminProto-Oncogene ProteinsBCOR protein, humanCore Binding Factor Alpha 2 SubunitDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanNuclear ProteinsNucleophosminProto-Oncogene ProteinsRepressor ProteinsRUNX1 protein, humanSerine-Arginine Splicing FactorsSRSF2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05025098ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.